Mis-folded prion proteins have been linked to a number of neurological diseases including scrapie in sheep, bovine spongiform encephalopathy (BSE, “mad cow disease”) in cattle and Creutzfeldt-Jakob disease (CJD) in humans. A new study by researchers at Yale University now suggests a link between normal prion proteins and Alzheimer’s disease. The accumulation of insoluble amyloid plaques in the brain is a hallmark of Alzheimer’s disease. Soluble β-amyloid oligomers also accumulate in the brain and cause damage to neurons and synapses, although precisely how this happens is not clear. Using gene expression analysis, the Yale team identified normal, correctly folded, cellular prion protein (PrPc) as a cell surface receptor for oligomeric β-amyloid. PrPc binds β-amyloid oligomers with nanomolar affinity and the interaction does not require the infectious PrPSc conformation of prion protein that is linked to scrapie, BSE and CJD. Binding of β-amyloid was associated with a specific region on the prion protein and could be blocked by an antibody directed against this site. The team found two other receptors that also bind β-amyloid, but with weaker affinity than PrPc. β-Amyloid oligomers are known to interfere with long term potentiation (LTP), a process that may be linked to learning and memory. In brains from mice lacking PrPc, LTP was not affected by the presence of β-amyloid, suggesting that blocking the interaction between β-amyloid and PrPc may be a new way to treat Alzheimer’s disease. The normal function of PrPc is still under investigation.
The study is published in the February 26th issue of the journal Nature.
Related posts:
- Glimepiride Potential for Treatment of Prion Diseases Prion diseases comprise the transmissible spongiform encephalopathies, including scrapie in sheep, bovine spongiform encephalopathy (BSE, “Mad Cow” disease) in cattle...
- Calpain Inhibitors in Models of Alzheimer’s Disease Calpains are calcium-activated cysteine proteases which, when abnormally activated, can initiate degradation of proteins essential for neuronal survival. A report...
- GPCR Target for Alzheimer’s Disease Available treatments for Alzheimer’s disease offer relatively small symptomatic benefits and more effective treatments are much needed. β-Amyloid has been...
- Insulin Growth Factor Signalling in Alzheimer’s Disease Although family history and lifestyle choices play a role, ageing is recognised to be the largest single risk factor for...
- New Role for APP in Alzheimer’s Disease Cleavage of amyloid precursor protein (APP) by β- and γ-secretases into neurotoxic β-amyloid peptides is believed to play a leading...
Related posts brought to you by Yet Another Related Posts Plugin.
This entry was posted on Monday, March 2nd, 2009 at 9:26 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Entries (RSS)
[...] modulation of cell-surface PrPc may also have application in Alzheimer’s disease since it is a receptor for β-amyloid oligomers. Whether glimepiride is sufficiently CNS-penetrant to be effective remains to be seen. Bookmark [...]